Protara Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TARA Nasdaq 2836 www.protaratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protara Therapeutics, Inc.

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - May 31st, 2026 8:39 am
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - May 20th, 2026 6:00 am
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - May 18th, 2026 6:00 am
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC - May 15th, 2026 5:00 am
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - May 13th, 2026 6:00 am
One Protara Therapeutics Insider Raised Their Stake In The Previous Year - May 4th, 2026 4:15 am
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting - Apr 27th, 2026 2:05 pm
Protara Therapeutics: Q4 Earnings Snapshot - Mar 10th, 2026 6:10 am
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Mar 10th, 2026 6:00 am
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Mar 1st, 2026 6:36 pm
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - Feb 25th, 2026 1:12 am
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Feb 23rd, 2026 3:05 pm
Protara Therapeutics to Participate in Upcoming Investor Conferences - Feb 19th, 2026 6:00 am
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 2nd, 2026 2:05 pm
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium - Jan 22nd, 2026 6:00 am
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - Jan 12th, 2026 5:00 am
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 7th, 2026 6:00 am
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - Jan 7th, 2026 6:00 am
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - Jan 5th, 2026 6:00 am
Protara Announces Closing of $75 Million Public Offering - Dec 8th, 2025 2:05 pm